Neurocrine Biosciences, Inc.
12790 El Camino Real
San Diego
California
92121
United States
Tel: 858-617-7600
Fax: 858-617-7601
Website: http://www.neurocrine.com/
393 articles with Neurocrine Biosciences, Inc.
-
“Our alliance with Sanofi Genzyme has been foundational for Voyager as we optimized the development of capsids, transgenes and gene therapy delivery,” stated Andre Turenne, president and chief executive officer of Voyager. “We look forward to this new stage of the relationship and to advancing ou...
-
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders
6/11/2019
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data from two of its movement disorder programs, including INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD), and opicapone, an investigational adjunct treatment for Parkinson's disease.
-
Neurocrine Biosciences to Present at Goldman Sachs 40th Annual Global Healthcare Conference
6/4/2019
Neurocrine Biosciences, Inc. will present at the Goldman Sachs 40th Annual Global Healthcare Conference at 10:00 a.m. PT (1:00 p.m. ET) on Tuesday, June 11, 2019, in Rancho Palos Verdes, Calif. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the conference.
-
Neurocrine Biosciences to Present at Jefferies 2019 Global Healthcare Conference
5/30/2019
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Jefferies 2019 Global Healthcare Conference at 10:30 a.m. ET on Thursday, June 6, 2019, in New York. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the conference.
-
Biocom Appoints Additional Members to Board of Directors
5/29/2019
Biocom, the association representing the California life science industry, today announced that it has added Matt Abernethy, chief financial officer of Neurocrine Biosciences, and Sabrina Martucci Johnson, president and chief executive officer of Daré Biosciences, to its board of directors.
-
Neurocrine Biosciences Presents New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia, Demonstrating the Effect of Involuntary Movements on Patient Quality of Life
5/20/2019
Neurocrine Biosciences, Inc. announced new data from RE-KINECT, the largest real-world screening study to date of patients with clinician-confirmed possible tardive dyskinesia, demonstrating the effect of involuntary movements on patient health-related quality of life.
-
Neurocrine Biosciences to Present New Quality-of-Life Data Analysis from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2019 American Psychiatric Association Annual Meeting
5/16/2019
Neurocrine Biosciences, Inc. announced that it will present a new quality-of-life data analysis from RE-KINECT, the largest real-world screening study of patients with clinician-confirmed possible tardive dyskinesia, an involuntary movement disorder.
-
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
-
Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2019
5/7/2019
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Bank of America Merrill Lynch Health Care Conference 2019 at 10:00 a.m. PT (1:00 p.m. ET) on Tuesday, May 14, 2019, in Las Vegas. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the conference.
-
Neurocrine Biosciences Honors Mental Health Month and Raises Awareness of Tardive Dyskinesia and its Impact on Patients
5/6/2019
Mental Health Advocacy Community Recognizes and 25 States Declare Tardive Dyskinesia Awareness Week as Part of Mental Health Month to Raise Prominence of Tardive Dyskinesia and Highlight the Impact on the Lives of Patients
-
San Diego-based Neurocrine Biosciences presented data from two Phase III clinical trials of opicapone, a once-daily, oral catechol-O-methyltransferase (COMT) inhibitor for Parkinson’s disease.
-
Quite a few companies recently released results from late-stage clinical trials. Here’s a look at some of the top stories, from AveXis, Urovant, Lilly, and more.
-
Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson's Disease Patients
5/5/2019
More than 60% of Patients Treated with Once-Daily Opicapone 50 mg Experienced an Increase in Total ON Time of One Hour or Longer
-
Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting
5/5/2019
Results Confirm the Posterior Trajectory as an Additional Surgical Delivery Route for VY-AADC in Patients with Parkinson's Disease
-
Neurocrine Biosciences to Present Data Analyses on INGREZZA® (valbenazine) and Opicapone at the 2019 American Academy of Neurology Annual Meeting
4/30/2019
Long-Term Data from Two Phase III Trials Show INGREZZA Sustained Improvement in Tardive Dyskinesia Symptoms in Patients Taking Concomitant Medications for Psychiatric Disorders
-
Neurocrine Biosciences Reports First Quarter 2019 Financial Results
4/29/2019
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended March 31, 2019 and provided an update on the launch of INGREZZA® (valbenazine) and its clinical development programs
-
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2019 Financial Results
4/8/2019
Conference Call and Webcast Scheduled for Monday, April 29
-
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
3/5/2019
Neurocrine Biosciences, Inc. announced that Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the following investor conferences
-
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results
2/5/2019
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended December 31, 2018 and provided an update on the launch of INGREZZA® (valbenazine) and its clinical development programs.
-
The area is home to numerous well-known players in the pharma industry, including Abbott, Iovance, Gossamer Bio, Crown Biosciences, Illumina, Human Longevity and many, many more.